MARKET

LGND

LGND

Ligand Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

115.06
+2.85
+2.54%
After Hours: 115.06 0 0.00% 16:00 07/10 EDT
OPEN
110.51
PREV CLOSE
112.21
HIGH
117.34
LOW
110.50
VOLUME
226.88K
TURNOVER
--
52 WEEK HIGH
124.97
52 WEEK LOW
57.24
MARKET CAP
1.85B
P/E (TTM)
-33.4739
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average LGND stock price target is 176.33 with a high estimate of 229.00 and a low estimate of 134.00.

EPS

LGND News

More
Sermonix Pharmaceuticals to Collaborate With Eli Lilly and Company in Studying Combination of Lasofoxifene and Lillys CDK 4 and 6 Inhibitor, Abemaciclib, in Metastatic Breast Cancer
GlobeNewswire · 2d ago
Sermonix teams up with Lilly in study of doublet therapy in type of breast cancer
Seeking Alpha - Article · 2d ago
Sermonix Pharmaceuticals To Collaborate With Eli Lilly And Company. In Studying Combination of Lasofoxifene And Lilly's CDK 4 And 6 Inhibitor, Abemaciclib, In Metastatic Breast Cancer
COLUMBUS, Ohio, July 08, 2020 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female oncology products in the precision medicine metastatic
Benzinga · 2d ago
LGND or RGEN: Which Is the Better Value Stock Right Now?
Zacks · 07/03 16:40
Ultragenyx's Dojolvi Gets FDA Nod to Treat Rare Disease
Ultragenyx (RARE) gets FDA approval forDojolvi for the treatment of pediatric and adult patients with molecularly confirmed long-chain fatty acid oxidation disorders.
Zacks · 07/01 16:11
IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2
IPA Confirms Discovery of Fully Human, Potent, Neutralizing Antibodies Targeting SARS-CoV-2
CNW Group · 06/29 16:48
Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD
Zacks · 06/29 16:44
Vertex's Triple Combo Cystic Fibrosis Pill Gets CHMP Backing
Zacks · 06/29 14:12

Industry

Biotechnology & Medical Research
-0.77%
Pharmaceuticals & Medical Research
-0.48%

Hot Stocks

Symbol
Price
%Change

About LGND

Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.
More

Webull offers kinds of Ligand Pharmaceuticals Inc. stock information, including NASDAQ:LGND real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGND stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LGND stock methods without spending real money on the virtual paper trading platform.